We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

WKL:EURONEXT AMSTERDAMWolters Kluwer N.V. Analysis

Data as of 2026-03-10 - not real-time

€67.16

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Wolters Kluwer (WKL.AS) trades at €67.16, sitting above its 20‑day SMA (≈€64.7) but well below the 50‑day (≈€75.4) and 200‑day (≈€106.3) averages, confirming a bearish technical backdrop. The RSI of 44.8 signals modest momentum, while the MACD histogram is positive, giving a bullish signal despite the overall bearish trend. Price action hovers near the identified resistance of €71.0 and comfortably above the support at €59.0. Fundamentally, the stock appears cheap on a PE basis (11.9× vs. industry 29.4×) and offers a solid dividend yield of 3.67% with a 43% payout ratio, but the DCF fair value of €49.4 suggests it is priced above intrinsic estimates. Recent material news includes the launch of the “Libra” legal‑tech platform and a series of share‑buyback programmes in January‑February 2026, both of which signal management confidence and could provide short‑term price support.
Overall, the valuation sits in a fair range with a tilt toward value characteristics, the dividend appears sustainable given cash flow coverage, and the primary risks stem from high leverage (debt‑to‑equity > 600) and elevated short‑term volatility (≈56% 30‑day).

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bearish SMA alignment
  • Positive MACD histogram indicating limited upside
  • Recent share‑buyback activity supporting price floor

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation upside vs. industry peers (low PE)
  • Product innovation (Libra platform) expanding revenue streams
  • Attractive dividend yield and ongoing buyback programme

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • High leverage and low ROE limiting growth potential
  • Sustainable dividend supported by cash flow
  • Diversified global exposure mitigating single‑market risk

Key Metrics & Analysis

Financial Health

Revenue Growth1.60%
Profit Margin21.36%
P/E Ratio11.9
ROE111.65%
ROA10.01%
Debt/Equity623.06
P/B Ratio19.0
Op. Cash Flow€1.7B
Free Cash Flow€1.0B
Industry P/E29.4

Technical Analysis

TrendBearish
RSI44.8
Support€59.00
Resistance€70.98
MA 20€64.70
MA 50€75.40
MA 200€106.27
MACDBullish
VolumeStable
Fear & Greed Index76.91

Valuation

Fair Value€49.37
Target Price€114.71
Upside/Downside70.81%
GradeFair
TypeValue
Dividend Yield3.67%

Risk Assessment

Beta0.03
Volatility56.34%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.